- Mission [1]
- FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science
and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities
to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency
preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical
products; establish an effective tabacco regulation, prevention, and control program; and manage for organizational excellence
and accountability. The Blood Product Advisory Committee supports FDA's mission and strategic action plan by reviewing and
evaluating data on the safety and effectiveness of blood products intended for use in the diagnosis, prevention or treatment
of human diseases. The Committee also considers the quality and relevance of FDA's research program which, provides scientific
support for the regulation of these products. The Committee supports FDA's mission by using science-based risk management
in all of its activities. The Committee recommendations provide the most health promotion and protection at the least cost
for the public. This Committee assists the Agency in ensuring timely, high quality, cost-effective processes for review of
new technologies/pre-market submissions, effective communication and working relationships with stakeholders to enhance U.S.
and global health outcomes, accurately analyzing risks associated with medical products, facilitating the development and
availability of medical countermeasures to limit the effects of a terrorist attack on the civilian and military populations,
protecting the safety and security of biologics (vaccines, blood, and blood products) all key components of FDA's strategic
plan objectives.
|
